Goldman Sachs’s Kiora Pharmaceuticals KPRX Stock Holding History

Goldman Sachs’s Portfolio KPRX Stock Details KPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-37	Closed	-$8K	–	6591
2022 Q1	$8K	Buy	+37	New	+$9.67K	﹤0.01%	6489

Other funds holding KPRX

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Goldman Sachs's KPRX Position: Q2 2022 in Review

Goldman Sachs sold out of Kiora Pharmaceuticals (KPRX) in Q2 2022, closing a stake of 37 shares — an estimated $8K sold.

Goldman Sachs first reported a position in KPRX in Q1 2022 and held it in 1 quarter. The position peaked at $8K in Q1 2022. 13 funds tracked by Wall St. Rank hold KPRX as of Q2 2022.

Goldman Sachs reported no remaining Kiora Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Goldman Sachs sold 37 Kiora Pharmaceuticals shares in Q2 2022, an estimated $8K.
Goldman Sachs first reported a position in Kiora Pharmaceuticals in Q1 2022 and held it in 1 quarter.
Goldman Sachs's Kiora Pharmaceuticals position peaked at $8K in Q1 2022.
13 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q2 2022.

Based on Goldman Sachs's 13F filing for Q2 2022, filed 15 Aug 2022.